Siemens Healthineers Navigates Diverging Paths in Neurology and Diagnostics

Siemens Healthineers faces diagnostics headwinds and a corporate spin-off while launching promising new blood-based Alzheimer's research assays, creating a complex investment picture.

Siemens Healthineers finds itself navigating a complex landscape, with promising developments in neurology research tools emerging against a backdrop of persistent challenges in its core diagnostics business. This divergence is creating a unique dynamic for the company and its investors.

Diagnostics Division Faces Headwinds

The company's diagnostics segment reported a 3% contraction in the first quarter of fiscal 2026. This decline is attributed primarily to ongoing difficulties within the Chinese market. Despite this pressure, the group confirmed its full-year outlook for comparable revenue growth of between 5% and 6%. Current growth drivers are the imaging and advanced therapy divisions, rather than diagnostics.

Adding to the financial pressure is an anticipated negative tariff impact of up to €500 million for the current fiscal year. Furthermore, a significant corporate transition is underway: the planned separation from its parent company, Siemens AG. Approximately 30% of Siemens Healthineers shares are slated to be distributed directly to Siemens shareholders via a spin-off. The market expects further details on this transaction early in the second quarter of 2026.

The company's share price currently trades near its 52-week low of €37.22, representing a level roughly 17% below its 200-day moving average. Market observers suggest the promising neurology pipeline alone is unlikely to reverse this trend in the near term, given the structural softness in diagnostics and the uncertainty surrounding the corporate separation.

Neurology Research Portfolio Expands

In a significant move for Alzheimer's disease research, Siemens Healthineers has launched two fully automated assays for research use only. The Atellica IM pTau217 and the Atellica IM Brain Derived Tau (BDTau) assays enable quantitative measurements from blood samples. This technology offers a less invasive alternative to traditional cerebrospinal fluid analysis, which requires a lumbar puncture. The addressable market is substantial, considering nearly ten million new dementia diagnoses are made globally each year.

These tests are not approved for guiding clinical decisions but are intended solely for research applications. They run on the widely adopted Atellica analyzer platforms and are incorporated into several multi-cohort studies. These include collaborations with PREDICTOM, ACCESS-AD, and the Banner Sun Health Research Institute. Data from these assays was presented in March at the AD/PD conference in Copenhagen.

Beyond these new releases, the company already markets a CE-certified neurofilament light chain assay used in managing Multiple Sclerosis. Its development pipeline also includes a marker for ApoE-?4, a protein associated with both Alzheimer's disease and cardiovascular conditions. These steps are gradually establishing neurology as a distinct and growing research focus area for the firm.